Tretinoin (also known as Retinoic Acid) is the topical treatment of choice for acne.  However, it is poorly soluble and is associated with irritation and dryness of the skin.  In the USA alone the sales for topical acne treatments in 2006 were USD1.3 billion of which topical prescription retinoids, such as tretinoin, contributed USD347 million.

Pre-clinical studies demonstrated both an increase in dermal absorption of tretinoin when formulated with Phosphagenics’ unique drug delivery technology (TPM®), and a significant reduction in irritation scores, while limiting the delivery of tretinoin into the system circulation, compared to tretinoin alone.

Phosphagenics also obtained favourable results in a Phase I human safety and irritation clinical trial conducted in the USA.

A new formulation with the ability to deliver greater absorption of tretinoin, reduce irritation and dryness and limit systemic circulation should significantly increase the topical prescription retinoids market.